NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held June 13-16, 2019, in Amsterdam. The abstract summarizes preliminary...
Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association (“EHA”) Congress, June 15, 2019 STRO-002 Phase 1 Clinical Trial Underway in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO,...
American Association for Cancer Research (AACR) 2019 – STRO-002 Abstract 3897
American Association for Cancer Research (AACR) 2019 Abstract 3897: Stability and safety evaluation of STRO-002, a site-specific anti-folate receptor alpha antibody-drug conjugate for the potential treatment of ovarian and endometrial cancers.
American Association for Cancer Research (AACR) 2019 – STRO-002 Poster
American Association for Cancer Research (AACR) 2019 A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-002, An Anti-Folate Alpha (FolRα) Antibody Drug Conjugate, In Patients With Advanced Epithelial Ovarian Cancer (Including...
American Association for Cancer Research (AACR) 2019 – STRO-001 Poster
A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-001, An Anti-CD74 Antibody Drug Conjugate, In Patients With Advanced B-Cell Malignancies, NCT03424603
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central...
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif., April 1, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
STRO-002, Sutro’s second clinical program, is designed to deliver “toxic payloads” to kill cancer cells Sutro plans to enroll up to 160 patients in open-label, multicenter study SOUTH SAN FRANCISCO, Calif., March 15, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today...
Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 5, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott...
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company SOUTH SAN FRANCISCO, Calif., Jan. 29, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced the appointment of Andreas Maderna, Ph.D., as vice president of chemistry. Dr. Maderna has extensive...